Risk-Based Screening Works as Well as Yearly Checks After 40 in Finding Breast CancersRisk-Based Screening Works as Well as Yearly Checks After 40 in Finding Breast Cancers
A study of more than 45,000 women found that screening women according to their level of risk was as effective in detecting tumors as the one-size-fits-most screening currently recommended.
Study Makes the Case for Replacing Annual Breast Cancer ScreeningStudy Makes the Case for Replacing Annual Breast Cancer Screening
(MedPage Today) — SAN ANTONIO — Risk-based breast cancer screening proved noninferior for detecting clinically significant tumors in a randomized trial, though outside experts raised concerns and a major medical group said the findings do not…
More Support for Omitting Lymph Node Biopsy in Low-Risk Early Breast CancerMore Support for Omitting Lymph Node Biopsy in Low-Risk Early Breast Cancer
(MedPage Today) — SAN ANTONIO — Many patients with early breast cancer can safely skip sentinel lymph node biopsy (SLNB), results of a large Dutch study suggested.
After 5 years, the regional recurrence-free survival (RRFS) rate was 96.6…
Pre-Op MRI Shows ‘No Clinical Benefit’ in Early Breast CancerPre-Op MRI Shows ‘No Clinical Benefit’ in Early Breast Cancer
(MedPage Today) — SAN ANTONIO — Preoperative MRI for staging patients with early, hormone receptor (HR)-negative breast cancer didn’t result in improved oncologic outcomes or improved clinical care, according to a phase III study presented…
Menopausal hormone therapy may not pose breast cancer risk for women with BRCA mutations, analysis suggestsMenopausal hormone therapy may not pose breast cancer risk for women with BRCA mutations, analysis suggests
Using menopausal hormone therapy (MHT) was not associated with an increased risk of breast cancer in women with inherited mutations in the BRCA1 or BRCA2 genes, according to the results of a matched prospective analysis presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9–12, 2025.
Mobile health tool may improve quality of life for adolescent and young adult breast cancer survivorsMobile health tool may improve quality of life for adolescent and young adult breast cancer survivors
A mobile health (mHealth) intervention for adolescent and young adult breast cancer survivors that offered tailored support by monitoring electronic patient-reported outcomes (ePROs) significantly improved quality of life and symptoms related to vaginal and arm problems, according to results from a randomized clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9–12, 2025.
Acupuncture may help improve perceived breast cancer-related cognitive difficulties over usual careAcupuncture may help improve perceived breast cancer-related cognitive difficulties over usual care
Real and sham acupuncture were more effective at improving breast cancer survivors’ perceived cognitive impairment compared with usual care, while real acupuncture was superior to sham acupuncture in improving objective cognitive function, according to results from the randomized ENHANCE Phase II clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9–12, 2025.
Phase I trial finds breast cancer vaccine triggers an immune response and is safePhase I trial finds breast cancer vaccine triggers an immune response and is safe
Cleveland Clinic researchers are presenting final Phase I data from their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.
Phase I trial finds breast cancer vaccine triggers an immune response and is safePhase I trial finds breast cancer vaccine triggers an immune response and is safe
Cleveland Clinic researchers are presenting final Phase I data from their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.
Triple-negative breast cancer vaccine shows promise in early clinical trialTriple-negative breast cancer vaccine shows promise in early clinical trial
When Chase Johnson was 31, her dog began acting strange.